KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Common Equity (2019 - 2025)

Ginkgo Bioworks Holdings' Common Equity history spans 7 years, with the latest figure at $508.6 million for Q4 2025.

  • For Q4 2025, Common Equity fell 28.97% year-over-year to $508.6 million; the TTM value through Dec 2025 reached $508.6 million, down 28.97%, while the annual FY2025 figure was $508.6 million, 28.97% down from the prior year.
  • Common Equity reached $508.6 million in Q4 2025 per DNA's latest filing, down from $559.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.7 billion in Q4 2022 to a low of $355.8 million in Q2 2021.
  • Average Common Equity over 5 years is $1.1 billion, with a median of $1.0 billion recorded in 2023.
  • Peak YoY movement for Common Equity: surged 341.91% in 2022, then crashed 44.59% in 2024.
  • A 5-year view of Common Equity shows it stood at $1.6 billion in 2021, then increased by 10.78% to $1.7 billion in 2022, then crashed by 36.81% to $1.1 billion in 2023, then plummeted by 34.73% to $716.1 million in 2024, then fell by 28.97% to $508.6 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Common Equity are $508.6 million (Q4 2025), $559.8 million (Q3 2025), and $613.0 million (Q2 2025).